Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* patients having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 18 years and are willing to received eradication therapy.~Exclusion Criteria:~* pregnant or nursing woman~* serious concomitant illness and malignant tumor of any kind~* history of hypersensitivity to test drugs~* serious bleeding during the course of this ulcer~* previous gastric surgery~* receiving bismuth salts, proton pump inhibitors, or antibiotics in the previous month.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- high dose dual therapy (Type: EXPERIMENTAL): group A1 and A2 - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
- sequential therapy (Type: EXPERIMENTAL): group B1 and B2 - sequential therapy (rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days)
- clarithromycin-based triple therapy (Type: ACTIVE_COMPARATOR): group C1 - clarithromycin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days)
- levofloxacin-based triple therapy (Type: ACTIVE_COMPARATOR): group C2 - levofloxacin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).